Editas and AskBio Team Up to Develop Novel Treatments for Neurological Diseases

Rare Daily Staff

The gene editing company Editas Medicine is teaming up with AAV gene therapy developer Asklepios BioPharmaceutical (AskBio) in a strategic research collaboration to explore in vivo delivery of genome editing medicines to treat neurological diseases.

The collaboration brings together AskBio’s capsid development, clinical stage AAV vector delivery system, and manufacturing expertise with Editas Medicine’s genome editing technologies to potentially develop novel medicines for patients with high unmet need. 

“We believe that together we can deliver innovative genome editing medicines to the nervous system and rapidly advance medicines to treat neurological diseases and help patients in great need,” said Charles Albright, executive vice president and chief scientific officer, Editas Medicine.

The companies will work together to find solutions to severe diseases where there are few or no treatment options.

“With this shared goal in mind, we will combine our technologies to create an innovative approach to treating neurological diseases,” said Jude Samulski, co-founder, AskBio.

Photo: Jude Samulski, co-founder, AskBio